Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905567 | 0.87 | USP30 (0.42) | USP5SMN1; SMN2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL2903462 | 0.84 | BDKRB1 (0.45) | SMN1; SMN2L3MBTL1ALDH1A1HPGDLMNA | |
| SCHEMBL3749390 | 0.83 | BDKRB1 (0.44) | SMN1; SMN2L3MBTL1ALDH1A1HPGDLMNA | |
| SCHEMBL15103777 | 0.83 | USP5 (0.49) | USP5SMN1; SMN2CYP2D6CYP2C19TP53 | |
| SCHEMBL2905688 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1HPGDLMNAMAPT | |
| SCHEMBL3751486 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1HPGDLMNAMAPT | |
| SCHEMBL2905310 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1HPGDLMNAMAPT | |
| SCHEMBL2903213 | 0.80 | ALDH1A1 (0.51) | USP5SMN1; SMN2CYP2D6CYP2C19L3MBTL1 | |
| SCHEMBL2903718 | 0.80 | POLB (0.41) | SMN1; SMN2ALDH1A1HPGDLMNAMAPT | |
| SCHEMBL3757584 | 0.78 | USP5 (0.52) | USP5SMN1; SMN2CYP2D6CYP2C19THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, NPBWR1 | USP5 3400/4885SMN1; SMN2 4628/4885CYP2D6 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.